Wednesday, July 8, 2026

pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX

CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker CPRX. Primary therapeutic focus areas include Hemophilia A With Inhibitor, Hemophilia A, Hemophilia B,

355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US HQ
2002 Founded
179 Employees
Public company Type
CPRX · NYSE Ticker
Company details
Status
Public
HQ
355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
Founded
2002
Employees
179
Programs
23
Drugs
20
Patents
61
Clinical program

CPP-109 vigabatrin

Phase 2 · small molecule · Methamphetamine Dependence

CPP-109 vigabatrin for Methamphetamine Dependence is a Phase 2 program (small_molecule) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

← All CATALYST PHARMACEUTICALS, INC. projects Phase 2 small molecule terminated

Internal code CPP-02001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CATALYST PHARMACEUTICALS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Methamphetamine Dependence
Status
terminated
Trials
1